Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

  1. Grande, E.
  2. Arranz, J.Á.
  3. De Santis, M.
  4. Bamias, A.
  5. Kikuchi, E.
  6. del Muro, X.G.
  7. Park, S.H.
  8. De Giorgi, U.
  9. Alekseev, B.
  10. Mencinger, M.
  11. Izumi, K.
  12. Schutz, F.A.
  13. Puente, J.
  14. Li, J.-R.
  15. O'Donnell, P.H.
  16. Kalebasty, A.R.
  17. Ye, D.
  18. Mariathasan, S.
  19. Bene-Tchaleu, F.
  20. Bernhard, S.
  21. Lee, C.
  22. Davis, I.D.
  23. Galsky, M.D.
Revue:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Année de publication: 2024

Volumen: 25

Número: 1

Pages: 29-45

Type: Article

DOI: 10.1016/S1470-2045(23)00540-5 GOOGLE SCHOLAR